摘要
耐多药结核病即结核分枝杆菌对包括异烟肼与利福平在内的至少两种一线抗结核药耐药的结核病。由于其病程长、经济负担高、治愈率低,且不同国家、地区药物耐药性存在较大差异,给全球结核病防控工作带来了巨大挑战。因此积极探讨耐多药结核病的有效治疗是当前亟待解决的课题。目前化学治疗仍是耐多药结核病的主要治疗方式,本文针对耐多药结核病化学治疗进行阐述,并讨论目前存在的局限性与不足,以期为耐多药结核病临床治疗及多学科合作提供参考或借鉴。
Multidrug-resistant tuberculosis(MDR-TB)means that Mycobacterium tuberculosis is resistant to at least two first-line anti-tuberculosis drugs,including isoniazid and rifampicin.Because of its long course of tuberculosis,high economic burden,low cure rate and great differences in drug resistance in different countries and regions,this disease has posed great challenges to the global tuberculosis prevention and control.Therefore,it is an urgent task to actively explore the effective treatment of multidrug-resistant tuberculosis.At present,chemotherapy is yet the main treatment for MDR-TB.This paper expounds on chemotherapy for MDR-TB,and discusses the existing limitations and shortcomings in order to provide some reference for clinical treatment and multidisciplinary cooperation of MDR-TB.
作者
刁婷婷
刘超
张红吉
欧阳兵
李晓非
Diao Tingting;Liu Chao;Zhang Hongji;Ouyang Bing;Li Xiaofei(Depatment of Science Education Academic,Yunnan Provincial Center for Infectious Diseases Clinical Medicine,Kunming Third People's Hospital,Kunming 650041,China)
出处
《兰州大学学报（医学版）》
2024年第11期87-94,共8页
Journal of Lanzhou University（Medical Sciences）
基金
云南省科技厅高校联合重点项目(2020001BA070001-136)
昆明市科技计划项目(2023-1-NS-008)。
关键词
耐多药
结核病
化学治疗
结核分枝杆菌
进展
multidrug-resistant
tuberculosis
chemotherapy
mycobacterium tuberculosis
progress
